BIAFBioAffinity Technologies Inc
$0.8435
$0.00
(0.00%)
Overnight
Reported EarningsMay 8
Mkt Cap$5.1M
Vol487,899.00
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs (siRNAs) that kill squamous and basal skin cancer...
Business Wire
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering PR Newswire JERSEY CITY, N.J., June 18, 2026 JERSEY CITY,N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a...
PR Newswire
bioAffinity Technologies Announces Closing of $3.2 Million Offering
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the closing of its previously announced public offering of securities as described...
Business Wire
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering PR Newswire JERSEY CITY, N.J., June 17, 2026 JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a...
PR Newswire
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced that it has priced a Public Offering of securities as described below for aggregate...
Business Wire
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage lung cancer, announced a webinar on July 21, 2026, featuring clinical experts discussing emerging approaches to...
Business Wire
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath Lungs expanding role in pulmonary, oncology and surgical...
Business Wire
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the Mexican Institute of...
Business Wire
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
Zacks
bioAffinity Technologies Reports Record Monthly CyPath Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest BIAF News
ViewbioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
Business Wire
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
PR Newswire
bioAffinity Technologies Announces Closing of $3.2 Million Offering
Business Wire
Advertisement|Remove ads.